Zandman Daniel B, Peppercorn Mark A
Harvard Medical School, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Patient Prefer Adherence. 2009 Nov 3;3:87-92. doi: 10.2147/ppa.s3964.
Mesalamine and its derivatives are effective and well-tolerated therapies for ulcerative colitis. However, patient adherence to traditional mesalamine-based therapy is poor, and is often limited by heavy pill burdens and frequent dosing intervals. This can lead to ineffective disease control, impaired quality of life, and preventable morbidity and mortality. Previous studies have suggested that a once-daily mesalamine regimen would be strongly adhered to in the outpatient setting, but at that time no such formulation of mesalamine existed. In 2007, clinical trial data showed a novel, once-daily, multi-matrix (MMX) formulation of mesalamine to be effective in both remission induction and remission maintenance. This breakthrough in drug delivery allowed the unification of an effective therapeutic with a formulation that enables outpatients to be increasingly adherent to their medication. In theory, this might result in improved outpatient disease control and a decreased number of flares. As the use of MMX mesalamine increases, studies examining the outpatient community adherence rate need to be performed.
美沙拉嗪及其衍生物是治疗溃疡性结肠炎的有效且耐受性良好的疗法。然而，患者对传统美沙拉嗪疗法的依从性较差，且常常受限于沉重的药丸负担和频繁的给药间隔。这可能导致疾病控制不佳、生活质量受损以及可预防的发病率和死亡率。先前的研究表明，门诊患者会强烈坚持每日一次的美沙拉嗪治疗方案，但当时尚无此类美沙拉嗪制剂。2007年，临床试验数据显示，一种新型的、每日一次的多基质（MMX）美沙拉嗪制剂在诱导缓解和维持缓解方面均有效。这种药物递送方面的突破使得有效的治疗方法与一种能使门诊患者越来越坚持用药的制剂得以统一。从理论上讲，这可能会改善门诊患者的疾病控制情况并减少病情发作次数。随着MMX美沙拉嗪使用的增加，需要开展研究来考察门诊患者群体的依从率。
